News Clinical

New cell-based immunotherapy offered for melanoma

The Source •
Washington University physicians at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, will be among the first in the nation to administer a new cell-based immunotherapy to eligible patients with melanoma. Tumor-infiltrating lymphocyte therapy has received approval from the Food and Drug Administration for some patients with metastatic melanoma. (Image: Getty Images)
View Content

Siteman Cancer Center, based at Barnes-Jewish Hospital and the School of Medicine, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.